← Eichor
Study identifier: NCT06939088 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder

Condition: Alcohol Use Disorder · Alcohol Abuse/Dependence · Alcohol Dependence  ·  Sponsor: Anders Fink-Jensen, MD, DMSci

PhasePhase 2
Planned participants108
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for the treatment of type 2 diabetes and obesity, have shown promise as a novel treatment for alcohol use disorder (AUD). This study aims to investigate whether the Glucose-dependent Insulinotropic Polypeptide/GLP-1RA tirzepatide will reduce alcohol consumption in patients with a dual diagnosis of AUD and schizophrenia, a population in dire need of improved treatment options. To further investigate the neurobiological underpinnings of a potential dampening effect on alcohol consumption, functional magnetic resonance imaging (fMRI) brain scans will be applied. The key anticipated outcomes include: * decreased alcohol consumption and * reduced alcohol cue-induced brain activity in the GIP/GLP-1-treated patient group compared with the placebo group. To the best of the investigators knowledge, this has never been examined before.

This description comes directly from the study's public registry record.

Talk to the study team

Søren B Jensen, MD  ·  +45 60294963  ·  soeren.broegger.jensen@regionh.dk

Anders Fink-Jensen, MD, DMSc  ·  +45 22755843  ·  anders.fink-jensen@regionh.dk

Always discuss trial participation with your own doctor first.

Locations (2)

Department of Psychiatry, Aalborg University HospitalAalborg, Denmark, DenmarkRecruiting
Psychiatric Center Copenhagen, Frederiksberg HospitalFrederiksberg, Denmark, DenmarkRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06939088